Edition:
United Kingdom

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

6.95USD
2:53pm GMT
Change (% chg)

$0.15 (+2.21%)
Prev Close
$6.80
Open
$6.80
Day's High
$6.95
Day's Low
$6.75
Volume
6,898
Avg. Vol
11,139
52-wk High
$8.14
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Aeglea Biotherapeutics announces clinical collaboration with Merck
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer.Aeglea Bio Therapeutics Inc - ‍collaboration agreement is between Aeglea Biotherapeutics and Merck, through a subsidiary​.Aeglea Bio Therapeutics Inc - ‍additional details of collaboration were not disclosed​.Aeglea Bio Therapeutics Inc - ‍enrollment to multicenter phase 1/2 study​ is expected to begin in Q1 of 2018.  Full Article

Aeglea Biotherapeutics Qtrly loss per share $0.46
Tuesday, 9 Aug 2016 

Aeglea Bio Therapeutics Inc : Aeglea biotherapeutics announces second quarter 2016 financial results . Q2 revenue $1.4 million versus $3.4 million . Qtrly loss per share $0.46 .Management believes that co has sufficient capital resources to fund anticipated operations through q1 of 2018.  Full Article

Aeglea Biotherapeutics receives FDA fast track designation for AEB1102
Monday, 23 May 2016 

Aeglea Biotherapeutics Inc : Aeglea Biotherapeutics receives FDA fast track designation for AEB1102 for treatment of patients with hyperargininemia secondary to Arginase I deficiency . Expected to initiate a clinical trial in U.S. For AEB1102, in patients with Arginase I deficiency, in first half of 2016 .Aeglea biotherapeutics receives FDA fast track designation for AEB1102 for the treatment of patients with hyperargininemia secondary to Arginase I deficiency.  Full Article

Aeglea Biotherapeutics Q1 net loss per share attributable to common stockholders $7.10
Thursday, 19 May 2016 

Aeglea Biotherapeutics Inc : Has sufficient capital resources to fund anticipated operations through Q1 of 2018 . Grant revenue of $0.9 million was recognized in Q1 of 2016 .Qtrly net loss per share attributable to common stockholders $7.10.  Full Article

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer